Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test

The Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not think the drug will find utility beyond patients with liver-related risk factors.